These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 25835106)

  • 1. P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters.
    Kımıloğlu Şahan E; Erdoğan N; Ulusoy İ; Samet E; Akyıldız İğdem A; Gönüllü D
    Turk J Gastroenterol; 2015 Mar; 26(2):104-11. PubMed ID: 25835106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
    Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
    Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synaptophysin-Ki67 double stain: a novel technique that improves interobserver agreement in the grading of well-differentiated gastrointestinal neuroendocrine tumors.
    Matsukuma K; Olson KA; Gui D; Gandour-Edwards R; Li Y; Beckett L
    Mod Pathol; 2017 Apr; 30(4):620-629. PubMed ID: 28084345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gastrointestinal and pancreatic neuroendocrine tumors: a clinicopathologic and immunohistochemical study].
    Sun LM; Qiu XS; Wang EH
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):696-7. PubMed ID: 23302313
    [No Abstract]   [Full Text] [Related]  

  • 6. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
    BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chinese pathologic consensus for standard diagnosis of gastrointestinal and pancreatic neuroendocrine neoplasm].
    Chinese Pathologic Consensus Group for Gastrointestinal and Pancreatic Neuroendocrine Neoplasm
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):257-62. PubMed ID: 21616002
    [No Abstract]   [Full Text] [Related]  

  • 8. High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.
    Knösel T; Chen Y; Altendorf-Hofmann A; Danielczok C; Freesmeyer M; Settmacher U; Wurst C; Schulz S; Yang LL; Petersen I
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):397-403. PubMed ID: 22160160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariate analysis of metastasis‑related risk factors for patients with gastroenteropancreatic neuroendocrine tumors based on clinicopathological and endoscopic features.
    Tang C; Gong L; Zou W; Zhang J; Zhou Y; Wu X; Lu F; Ouyang C; Liu X
    Oncol Rep; 2016 Dec; 36(6):3343-3352. PubMed ID: 27748940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic features, cellular differentiation, PCNA and P53 expressions in gastrointestinal stromal tumors.
    Can B; Sökmensüer C
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccxliii-ccxlviii. PubMed ID: 15244191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of p16INK4a and p53 overexpression in endocrine tumors of the gastrointestinal tract.
    Li AF; Tsay SH; Liang WY; Li WY; Chen JY
    Am J Clin Pathol; 2006 Dec; 126(6):856-65. PubMed ID: 17074692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of CD44 expression in gastrointestinal neuroendocrine tumors.
    Lai CH; Shan YS; Sy ED; Hsieh YH; Tsai HW; Lee JC; Lin PW
    Hepatogastroenterology; 2005; 52(64):1071-6. PubMed ID: 16001632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
    Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
    Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.
    Ali AS; Grönberg M; Federspiel B; Scoazec JY; Hjortland GO; Grønbæk H; Ladekarl M; Langer SW; Welin S; Vestermark LW; Arola J; Österlund P; Knigge U; Sorbye H; Grimelius L; Janson ET
    PLoS One; 2017; 12(11):e0187667. PubMed ID: 29112960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuroendocrine neoplasm of digestive system with different grades: a clinicopathologic and prognostic study].
    Zhang MH; Liu YH; Luo XL; Lin XT; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):448-51. PubMed ID: 22932454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
    Özaslan E; Demir S; Karaca H; Güven K
    Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic Neuroendocrine Tumors.
    Salaria SN; Shi C
    Surg Pathol Clin; 2016 Dec; 9(4):595-617. PubMed ID: 27926362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.
    Milione M; Maisonneuve P; Spada F; Pellegrinelli A; Spaggiari P; Albarello L; Pisa E; Barberis M; Vanoli A; Buzzoni R; Pusceddu S; Concas L; Sessa F; Solcia E; Capella C; Fazio N; La Rosa S
    Neuroendocrinology; 2017; 104(1):85-93. PubMed ID: 26943788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
    Yao W; Wang W; Li G
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study.
    Larghi A; Capurso G; Carnuccio A; Ricci R; Alfieri S; Galasso D; Lugli F; Bianchi A; Panzuto F; De Marinis L; Falconi M; Delle Fave G; Doglietto GB; Costamagna G; Rindi G
    Gastrointest Endosc; 2012 Sep; 76(3):570-7. PubMed ID: 22898415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.